ClinicalTrials.gg
WithdrawnNCT05322616Updated May 31, 2023

Single-Ascending Dose Study of JK07 in Subjects With HFpEF

A Phase 1 interventional study of JK07 and Matching Placebo in Heart Failure With Preserved Ejection Fraction, sponsored by Salubris Biotherapeutics Inc. Withdrawn at 7 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-05-31.

Sponsored by Salubris Biotherapeutics Inc (part of Shenzhen Salubris Pharmaceuticals Co., Ltd.) · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.

Enrollment
1,522nd of 1,601
0 · median 65
Started
2022
with 106 others
Phase 1
118 of 2,157
18 open now
Registered
1,670th of 2,157
by date

Among the 2,157 studies in Heart Failure with a site in United States, this one is the 1,522nd largest by enrollment of the 1,601 interventional ones that give a count, is one of 107 that started in 2022, is one of 118 in phase 1, and was the 1,670th registered.

Heart Failure

6,332 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,157 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

A phase 1, randomized, double-blind, placebo-controlled single-ascending dose study to assess JK07 in adult subjects with heart failure with preserved ejection fraction.

Read the detailed description

A phase 1, randomized, double-blind, placebo-controlled single-ascending dose study to assess the safety and tolerability of JK07 in subjects 18 to 85 years of age with heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction >=45%. Eligible subjects must have maintained an optimal heart failure medical regimen for at least 1 month prior to informed consent, other than for diuretics, and as much as clinically appropriate, remain on the treatment regimen throughout the course of the study.

Initially 5 dose escalation cohorts are planned with the option of expansion to 7 dose escalation cohorts. Eight subjects will be randomized in a 6:2 ratio of JK07:placebo in each cohort.

The initial dose and dose escalation parameters will be dependent on the JK07.1.01 study Only doses established as safe in Study JK07.1.01 will be evaluated in this study and the highest JK07 dose administered will not exceed the lower of the top dose evaluated in Study JK07.1.01 or 2.5 mg/kg without amending the protocol. Subjects will be observed in a hospital or similar setting from prior to study drug infusion to completion of study assessments on Day 1.

Subjects will undergo blood sampling for clinical laboratory evaluation, including glucose fingerstick, and biomarkers, electrocardiogram, 2-dimensional transthoracic echocardiography, quality of life assessment and a a 6-minute walking test. Follow-up assessments will be performed at Day 2, 7, 15, 28, 60, 90, and 180.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction

Browse trials for

Keywords

  • heart failure
  • HFpHF
  • neuregulin-1
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Stable New Yok Heart Association () Class II or III HF diagnosis, evident at least 6 months prior to enrollment as confirmed by medical history.
  2. Documented prior objective evidence of heart failure as shown by 1 or more of the following criteria:

    1. Previous hospitalization for heart failure with documented radiographic evidence of pulmonary congestion.
    2. Elevated left ventricular (LV) end-diastolic pressure or pulmonary capillary wedge pressure at rest (≥15 mm Hg) or with exercise (≥25 mm Hg).
    3. Elevated level of NT-proBNP (>400 pg/mL) or brain natriuretic peptide (BNP) (>200 pg/mL).
    4. Echocardiographic evidence of medial E/e' ratio ≥ 15 or Left Atrial Volume (LAV) >58 mL in male patients or >52 mL in female patients.
  3. Adequate acoustic windows on screening resting TTE
  4. Documented structural abnormality consistent with HFpEF confirmed at the screening visit by clearly interpretable echocardiography assessment.
  5. Meets 1 or more of the following criteria at the initial screening measurement:

    1. A hs-cTnI >99th percentile
    2. NT-proBNP >300 pg/mL (if not in atrial fibrillation or atrial flutter) or >600 pg/mL (if in atrial fibrillation or atrial flutter), or if the screened participant is either of African descent or has a ≥30.0 kg/m2, a screening NT-proBNP >240 pg/mL (if not in atrial fibrillation or atrial flutter) or >480 pg/mL (if in atrial fibrillation or atrial flutter).
  6. Body mass index (BMI) ≥18 kg/m2 and ≤45 kg/m2
  7. Screening ≥9.0 g/dL, ≥100x109 /mL, (ANC) ≥1500/mL.
  8. Sexually mature biological male subjects must agree to use a medically accepted method of throughout the study and be willing and able to continue contraception until the end of the study (6-month time point).
  9. Biological females of must present with a negative blood pregnancy test, must not be lactating, and must agree to employ adequate birth control measures for the duration of the study and be willing and able to continue contraception until the end of the study (6-month time point).
  10. Subject is capable of giving signed .
  11. Subject is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

Cardiac-Related

  1. Participating in any other study and have received any other drug within 30 days prior to screening or 5-half-lives, whichever is longer, or any other investigational implanted device within 30 days prior to screening, or are taking part in a nonmedication study which, in the opinion of the Investigator, would interfere with study compliance or outcome assessments.
  2. Any past participation in a study that has investigated the NRG-1 pathway (e.g., Neucardin, cimaglermin).
  3. Has a prior diagnosis of hypertrophic cardiomyopathy or a known infiltrative or storage disorder causing HFpEF and/or cardiac hypertrophy, such as amyloidosis, Fabry disease, or Noonan syndrome with LV hypertrophy or a positive serum immunofixation result.
  4. Has a history of syncope within the last 6 months or sustained ventricular tachycardia with exercise within the past 6 months.
  5. Has persistent or permanent atrial fibrillation and is not therapeutically anticoagulated for at least the 4 weeks prior to the initial screening visit or is not adequately rate controlled within 6 months prior to according to investigator discretion.
  6. Has known moderate or severe aortic valve stenosis, hemodynamically significant mitral stenosis, or severe mitral or tricuspid regurgitation at informed consent.
  7. Has severe , or other severe pulmonary disease, requiring home oxygen, chronic nebulizer therapy, chronic oral therapy or hospitalized for pulmonary decompensation within 12 months of informed consent.
  8. Diagnosed with medically documented acute coronary syndrome within 3 months of screening or a medically documented acute myocardial infarction within 6 months of screening.
  9. Cardiac surgery, coronary artery revascularization, percutaneous coronary intervention, or valvuloplasty within 3 months prior to screening.
  10. Any subject who has received an indication for coronary revascularization within 3 months prior to screening.
  11. Any of the following confirmed by duplicate seated determinations on at least 3 consecutive readings (in clinic/office) following informed consent and prior to randomization:

    1. Systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) >100 mmHg
    2. Sustained SBP \<90 mmHg and/or DBP \<40 mmHg and/or symptomatic hypotension
    3. Sustained resting heart rate (HR) \<50 or ≥100 bpm or >110 bpm if chronic AF at Screening (Visit 1) or prior to randomization for >15 minutes in two episodes separated by one hour of observation
  12. Cerebrovascular accident or hospitalizations for cardiovascular (CV) causes other than routine percutaneous procedures (such as device, battery, generator changes or pacemaker lead insertion/replacement), including HF, chest pain, stroke, , or arrhythmias within 3 months prior to screening.
  13. Symptomatic carotid stenosis or transient ischemic attack or stroke within 60 days prior to informed consent.
  14. Has a history of resuscitated sudden cardiac arrest or a known history of appropriate implantable cardioverter-defibrillator (ICD) discharge for life-threatening ventricular arrhythmia. (Note: history of anti-tachycardia pacing (ATP) is allowed.)
  15. Subjects at screening have an abnormal or 12-lead abnormality, that, in the opinion of the Investigator, would affect efficacy or safety evaluation or place the subject at risk.
  16. History or evidence of clinically significant arrhythmias uncontrolled by drug therapy or use of an implantable defibrillator, long syndrome, or evidence of QT prolongation with QTcF >450 ms for males or QTcF >470 ms for females during screening and/or prior to randomization.

    Non-Cardiac Co-Morbidity

  17. Clinically significant renal dysfunction as measured by the estimated of \<45 mL/min/1.73m2 as calculated by local laboratory standards ( equation for estimation of creatinine clearance [CrCl] [Cockcroft and Gault 1976]) at screening, or a clinically significant change in renal function between screening and baseline.
  18. Clinically significant liver dysfunction as measured by: (ALT) >2.0 × the (ULN), alkaline phosphatase > 2.0 × ULN, aspartate aminotransferase (AST) >2.0 × ULN, or gamma glutamyl transferase (GGT) >2.0 × ULN or serum ≥ 1.5 × ULN at screening, or a clinically significant change in liver function between screening and baseline.
  19. Subjects with alteration of the coagulation panel ( [INR]) and/or prothrombin time (PT) ≥1.5 × the ULN; activated partial thromboplastin time (aPTT) ≥1.5 × ULN, or serum albumin ≤3 gm/dL. For subjects on warfarin or other anticoagulants, an INR (or PT) considered by the Principal Investigator as therapeutically appropriate will be allowed.
  20. Any subject who by Investigator's judgement, has a significant hematuria or proteinuria at screening.
  21. Concurrent treatment with Class Ia or III antiarrhythmic drugs if the dosage has been adjusted within 2 months prior to informed consent.
  22. Positive screening for antibodies, surface antigen, or virus antibodies.
  23. Known history of or active alcohol abuse (no more than 14 units/week for males or 7 units/week for females) or use of illicit drugs within 1 year prior to randomization (excluding recreational use of marijuana or cannabidiol [CBD]-based products).
  24. Other medical or psychiatric condition that, in the opinion of the Investigator, would preclude obtaining voluntary consent/assent or would confound the secondary objectives of study.
  25. A history of confirmed of any type or any pathologically confirmed pre-malignant condition (e.g., ductal carcinoma in situ, colonic polyp with premalignant diagnosis, or cervical atypia). All subjects are to undergo cancer screening following study enrollment in accordance with American Cancer Society Guidelines (See Appendix 1).
  26. Pregnant or lactating at screening.
  27. Subjects with clinically significant or poorly controlled disease including, but not limited to, endocrine (including diabetes and thyroid) disease, pulmonary (requires home oxygen, inhalants, steroids >10 mg prednisone equivalent or 2x baseline physiologic steroid replacement, primary pulmonary hypertension, history of pulmonary emboli), neurological or psychiatric (even mild), GI, hematological, urological, immunological, ophthalmic, or orthopedic diseases as determined by the Investigator.
  28. Any major surgical procedure within 1 month prior to screening or planned surgical procedure during the study period.
  29. Subjects who are not non-smokers or light smokers (no more than 5 cigarettes per day) and who cannot abstain from smoking from 2 weeks prior to the administration of IP through the end of the study.
  30. Subjects with orthopedic impairment which would prohibit credible or adequate assessment of 6MWT.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    JK07

    Single dose of intravenous JK07 administered by intravenous infusion over 60 minutes.

    Drug: JK07

  • Placebo comparator
    Matching Placebo

    Single dose of vehicle control administered by intravenous infusion over 60 minutes

    Drug: Matching Placebo

Interventions

  • DrugJK07

    Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1

  • DrugMatching Placebo

    Vehicle control

06

What researchers measure

Primary outcomes

  1. Safety Assessment

    Incidence and severity of treatment-emergent adverse events (safety and tolerability) by assessment of physical exams, injection site, vital signs and clinical laboratory tests.

    Time frame: Screening to Day 28

Other outcomes

  1. Natriuretic peptide

    Change in brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NTpro-BNP) change from baseline

    Time frame: Screening to Day 180

  2. Quality of Life - Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Change from baseline in the Clinical Summary Score of the KCCQ, a 23-item self-administered questionnaire that measures the patient's perception of their health status including symptoms of heart failure (eg., shortness of breath, fatigue, edema) and impact on physical and social function

    Time frame: Screening to Day 180

  3. 6-Minute Walking Test (6MWT)

    Change from baseline in the 6MWT

    Time frame: Screening to Day 180

  4. Two-dimensional Transthoracic Echocardiography (2D-TTE)

    Change from baseline to each assessment time point for 2D-TTE indices including but not limited to change in Echocardiographic evidence of medial E/e' ratio, Left Atrial Volume (LAV) in mL, LAV index in mL/m2, Left Atrial Area (LAA) in cm2

    Time frame: Screening to Day 180

07

Study locations

7 sites
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Harvard Medical School/Massachusetts General Hospital
    Boston, Massachusetts 02114-2696, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oregon Health and Science University Hospital
    Portland, Oregon 97239, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in May 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2022
First posted
Apr 12, 2022
StartActual
Oct 21, 2022
Primary completionActual
May 26, 2023
CompletionActual
May 26, 2023
Last update
May 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05322616
Responsible party
Sponsor
First posted
Apr 12, 2022
Start date
Oct 21, 2022
Primary completion
May 26, 2023
Completion
May 26, 2023
Last update
May 31, 2023

Study contacts

Wilson Tang, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JK07

Start the discussion